Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Cancer
    August 2021
  1. HUEPENBECKER SP, Sun CC, Fu S, Zhao H, et al
    Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33829.
    >> Share

    May 2021
  2. KIM SR, Tone A, Kim RH, Cesari M, et al
    Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Cancer. 2021 May 13. doi: 10.1002/cncr.33625.
    >> Share

    March 2021
  3. LEE CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, et al
    Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33517.
    >> Share

    February 2021
  4. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.
    Cancer. 2021 Feb 25. doi: 10.1002/cncr.33488.
    >> Share

    December 2020
  5. PRINTZ C
    Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.
    Cancer. 2020;126:5007.
    >> Share

    September 2020
  6. GHIRARDI V, Ronsini C, Trozzi R, Di Ilio C, et al
    Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
    Cancer. 2020 Sep 15. doi: 10.1002/cncr.33167.
    >> Share

    August 2020
  7. KIM SR, Tone A, Kim RH, Cesari M, et al
    Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer.
    Cancer. 2020 Aug 18. doi: 10.1002/cncr.33144.
    >> Share

    July 2020
  8. CORR BR, Moroney M, Sheeder J, Eckhardt SG, et al
    Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33073.
    >> Share

  9. LUTGENDORF SK, Penedo F, Goodheart MJ, Dahmoush L, et al
    Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
    Cancer. 2020 Jul 21. doi: 10.1002/cncr.33060.
    >> Share

    June 2020
  10. BLESSING AM, Santiago-O'Farrill JM, Mao W, Pang L, et al
    Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32985.
    >> Share

  11. WESTRICK AC, Bailey ZD, Schlumbrecht M, Hlaing WM, et al
    Residential segregation and overall survival of women with epithelial ovarian cancer.
    Cancer. 2020 Jun 2. doi: 10.1002/cncr.32989.
    >> Share

    May 2020
  12. POORT H, de Rooij BH, Uno H, Weng S, et al
    Patterns and predictors of cancer-related fatigue in ovarian and endometrial cancers: 1-year longitudinal study.
    Cancer. 2020 May 21. doi: 10.1002/cncr.32927.
    >> Share

  13. PRINTZ C
    Research teams unite to develop an early detection test for ovarian cancer.
    Cancer. 2020;126:2113.
    >> Share

    April 2020

  14. The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms.
    Cancer. 2020 Apr 13. doi: 10.1002/cncr.32867.
    >> Share

    March 2020
  15. RUSSO M, Newell JM, Budurlean L, Houser KR, et al
    Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
    Cancer. 2020 Mar 18. doi: 10.1002/cncr.32822.
    >> Share

    February 2020
  16. PRINTZ C
    Study finds that women with posttraumatic stress disorder have an increased risk of ovarian cancer.
    Cancer. 2020;126:468-469.
    >> Share

  17. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
    Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Cancer. 2020;126:549-558.
    >> Share

    January 2020
  18. GUO F, Scholl M, Fuchs EL, Berenson AB, et al
    BRCA testing in unaffected young women in the United States, 2006-2017.
    Cancer. 2020;126:337-343.
    >> Share

    December 2019
  19. VERGOTE I, Harter P, Chiva L
    Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
    Cancer. 2019;125 Suppl 24:4594-4597.
    >> Share

  20. BOOKMAN MA
    Can we predict who lives long with ovarian cancer?
    Cancer. 2019;125 Suppl 24:4578-4581.
    >> Share

  21. AREND R, Martinez A, Szul T, Birrer MJ, et al
    Biomarkers in ovarian cancer: To be or not to be.
    Cancer. 2019;125 Suppl 24:4563-4572.
    >> Share

  22. LEE JM, Minasian L, Kohn EC
    New strategies in ovarian cancer treatment.
    Cancer. 2019;125 Suppl 24:4623-4629.
    >> Share

  23. SEHOULI J, Grabowski JP
    Surgery in recurrent ovarian cancer.
    Cancer. 2019;125 Suppl 24:4598-4601.
    >> Share

  24. PIGNATA S, Pisano C, Di Napoli M, Cecere SC, et al
    Treatment of recurrent epithelial ovarian cancer.
    Cancer. 2019;125 Suppl 24:4609-4615.
    >> Share

  25. FUJIWARA K, Hasegawa K, Nagao S
    Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy.
    Cancer. 2019;125 Suppl 24:4582-4586.
    >> Share

  26. KOOLE SN, van Driel WJ, Sonke GS
    Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
    Cancer. 2019;125 Suppl 24:4587-4593.
    >> Share

  27. FRIEDLANDER ML
    Do all patients with recurrent ovarian cancer need systemic therapy?
    Cancer. 2019;125 Suppl 24:4602-4608.
    >> Share

  28. GONZALEZ-MARTIN A, Sanchez-Lorenzo L
    Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
    Cancer. 2019;125 Suppl 24:4616-4622.
    >> Share

  29. HARTER P, Heitz F, Ataseven B, Schneider S, et al
    How to manage lymph nodes in ovarian cancer.
    Cancer. 2019;125 Suppl 24:4573-4577.
    >> Share

    November 2019
  30. CRAFTON SM, Cohn DE, Llamocca EN, Louden E, et al
    Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries.
    Cancer. 2019 Nov 27. doi: 10.1002/cncr.32620.
    >> Share

  31. YANG WL, Lu Z, Guo J, Fellman BM, et al
    Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32582.
    >> Share

  32. SANTIAGO-O'FARRILL JM, Weroha SJ, Hou X, Oberg AL, et al
    Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32600.
    >> Share

    August 2019
  33. HAVRILESKY LJ, Yang JC, Lee PS, Secord AA, et al
    Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.
    Cancer. 2019 Aug 27. doi: 10.1002/cncr.32447.
    >> Share

  34. MULLINS MA, Peres LC, Alberg AJ, Bandera EV, et al
    Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.
    Cancer. 2019 Aug 15. doi: 10.1002/cncr.32451.
    >> Share

    June 2019
  35. KONDRASHOVA O, Scott CL
    Clarifying the role of EMSY in DNA repair in ovarian cancer.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32135.
    >> Share

  36. HOLLIS RL, Churchman M, Michie CO, Rye T, et al
    High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079.
    >> Share

    May 2019
  37. KAHN RM, Gordhandas S, Maddy BP, Baltich Nelson B, et al
    Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Cancer. 2019 May 31. doi: 10.1002/cncr.32203.
    >> Share

  38. PINSKY PF, Black A, Daugherty SE, Hoover R, et al
    Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32176.
    >> Share

    March 2019
  39. BAST RC JR, Matulonis UA, Sood AK, Ahmed AA, et al
    Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference.
    Cancer. 2019 Mar 5. doi: 10.1002/cncr.32004.
    >> Share

  40. DE ROOIJ BH, Ezendam NPM, Vos MC, Pijnenborg JMA, et al
    Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery.
    Cancer. 2019;125:788-797.
    >> Share

    January 2019
  41. MAO W, Peters HL, Sutton MN, Orozco AF, et al
    The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31935.
    >> Share

    December 2018
  42. TEMKIN SM, Mallen A, Bellavance E, Rubinsak L, et al
    The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31911.
    >> Share

  43. ESKANDER RN
    Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31902.
    >> Share

  44. BACKES FJ, Haag J, Cosgrove CM, Suarez A, et al
    Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31901.
    >> Share

    November 2018
  45. LAITMAN Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, et al
    Uterine cancer in Jewish Israeli BRCA1/BRCA2 mutation carriers.
    Cancer. 2018 Nov 29. doi: 10.1002/cncr.31842.
    >> Share

  46. FREY MK, Kopparam RV, Ni Zhou Z, Fields JC, et al
    Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Cancer. 2018 Nov 27. doi: 10.1002/cncr.31856.
    >> Share

  47. SMITH HJ, McCaw TR, Londono AI, Katre AA, et al
    The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31761.
    >> Share

    October 2018
  48. HOSKINS KF, Tejeda S, Vijayasiri G, Chukwudozie IB, et al
    A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31635.
    >> Share

    June 2018
  49. ARMER JS, Clevenger L, Davis LZ, Cuneo M, et al
    Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31570.
    >> Share

    February 2018
  50. IYER NS, Cartmel B, Friedman L, Li F, et al
    Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity.
    Cancer. 2018 Feb 13. doi: 10.1002/cncr.31239.
    >> Share

    December 2017
  51. STEWART SL, Harewood R, Matz M, Rim SH, et al
    Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5138-5159.
    >> Share

    November 2017
  52. LUTGENDORF SK, Thaker PH, Arevalo JM, Goodheart MJ, et al
    Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31078.
    >> Share

    September 2017
  53. LE GALLO M, Rudd ML, Urick ME, Hansen NF, et al
    The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30971.
    >> Share

  54. BOBER SL, Recklitis CJ, Michaud AL, Wright AA, et al
    Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30976.
    >> Share

    August 2017
  55. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    >> Share

    July 2017
  56. EVERETT EN
    The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer.
    Cancer. 2017 Jul 31. doi: 10.1002/cncy.21894.
    >> Share

  57. TOMAO F, D'Incalci M, Biagioli E, Peccatori FA, et al
    Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30830.
    >> Share

    June 2017
  58. BATEMAN NW, Dubil EA, Wang G, Hood BL, et al
    Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.
    Cancer. 2017 Jun 27. doi: 10.1002/cncr.30813.
    >> Share

  59. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    >> Share

    May 2017
  60. SCALICI JM, Arapovic S, Saks EJ, Atkins KA, et al
    Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Cancer. 2017;123:977-984.
    >> Share

  61. LONG ROCHE KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O, et al
    Risk-reducing salpingectomy: Let us be opportunistic.
    Cancer. 2017;123:1714-1720.
    >> Share

  62. BALASUBRAMANIAM S, Kim GS, McKee AE, Pazdur R, et al
    Regulatory considerations on endpoints in ovarian cancer drug development.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30652.
    >> Share

  63. IVY SP, Kohn EC
    Drug development and registration: Challenges and opportunities in ovarian cancer.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30645.
    >> Share

  64. ZENNARO L, Vanzani P, Nicole L, Cappellesso R, et al
    Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers.
    Cancer. 2017;125:341-348.
    >> Share

    April 2017
  65. PRINTZ C
    New treatment for patients with advanced ovarian cancer receives accelerated approval.
    Cancer. 2017;123:1286-1287.
    >> Share

    March 2017
  66. STARK DP, Cook A, Brown JM, Brundage MD, et al
    Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
    Cancer. 2017 Mar 24. doi: 10.1002/cncr.30657.
    >> Share

  67. SAMIMI G, Minasian LM
    Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30525.
    >> Share

  68. STIEKEMA A, Van de Vijver KK, Boot H, Broeks A, et al
    Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Mullerian origin from gastrointestinal cancer.
    Cancer. 2017;125:197-204.
    >> Share

    February 2017
  69. CRAGUN D, Weidner A, Lewis C, Bonner D, et al
    Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cancer. 2017 Feb 9. doi: 10.1002/cncr.30621.
    >> Share

    January 2017
  70. BUYS SS, Sandbach JF, Gammon A, Patel G, et al
    A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30498.
    >> Share

    December 2016
  71. GREENWALD ZR, Huang LN, Wissing MD, Franco EL, et al
    Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30529.
    >> Share

  72. GULATI R, Albertsen PC
    Insights from the PLCO trial about prostate cancer screening.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30472.
    >> Share

    November 2016
  73. GANESH K, Shah RH, Vakiani E, Nash GM, et al
    Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Cancer. 2016 Nov 22. doi: 10.1002/cncr.30424.
    >> Share

  74. RUNGRUANG BJ, Miller A, Krivak TC, Horowitz NS, et al
    What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Cancer. 2016 Nov 16. doi: 10.1002/cncr.30414.
    >> Share

    August 2016
  75. RYDZEWSKI NR, Strohl AE, Donnelly ED, Kanis MJ, et al
    Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30228.
    >> Share

    July 2016
  76. DEL CARMEN MG, Supko JG, Horick NK, Rauh-Hain JA, et al
    Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Cancer. 2016 Jul 15. doi: 10.1002/cncr.30196.
    >> Share

    June 2016
  77. GUINDALINI RS, Song A, Fackenthal JD, Olopade OI, et al
    Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Cancer. 2016;122:1913-20.
    >> Share

    May 2016
  78. LIAO ZW, Rodrigues MC, Poynter JN, Amatruda JF, et al
    Risk of second gonadal cancers in women and children with germ cell tumors.
    Cancer. 2016 May 6. doi: 10.1002/cncr.30014.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016